In a patient with statin induced immune-mediated necrotizing myopathy (+ anti-HMGCR antibodies), would you consider brepocitinib in the treatment algorithm?
Patient previously tried Methotrexate and Cellcept. How would you position it relative to other available options such as IVIG?
1 Answer
Mednet MemberInvited Expert
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)
Answered on
Unlike dermatomyositis, anti-HMGCR IMNM generally lacks a strong interferon signature. Therefore, the biologic rationale for JAK inhibition is less compelling, and I would not routinely consider brepocitinib in this setting.
Join for free or sign in to see the full answer